Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Reinhart Partners LLC.

Reinhart Partners LLC. boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 34.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 86,755 shares of the medical equipment provider's stock after purchasing an additional 22,220 shares during the period. Reinhart Partners LLC.'s holdings in Zimmer Biomet were worth $9,164,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Dunhill Financial LLC grew its stake in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet during the 3rd quarter worth $28,000. Bangor Savings Bank bought a new stake in shares of Zimmer Biomet in the third quarter valued at about $31,000. Brooklyn Investment Group bought a new stake in shares of Zimmer Biomet in the third quarter valued at about $35,000. Finally, Quarry LP purchased a new stake in Zimmer Biomet in the second quarter worth about $53,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

NYSE:ZBH traded up $0.82 during trading hours on Monday, hitting $105.36. 1,565,776 shares of the stock were exchanged, compared to its average volume of 1,740,803. The firm's fifty day moving average price is $107.97 and its 200 day moving average price is $108.00. Zimmer Biomet Holdings, Inc. has a 52-week low of $100.67 and a 52-week high of $133.90. The company has a market cap of $20.97 billion, a P/E ratio of 20.03, a P/E/G ratio of 1.96 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts' consensus estimates of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm's revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.65 EPS. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be paid a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.91%. Zimmer Biomet's dividend payout ratio (DPR) is 18.25%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ZBH shares. Oppenheimer lowered their target price on Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating for the company in a report on Tuesday, October 15th. BTIG Research dropped their price objective on Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a research report on Thursday, October 3rd. Royal Bank of Canada lifted their target price on Zimmer Biomet from $120.00 to $125.00 and gave the company an "outperform" rating in a research note on Monday, November 4th. Evercore ISI lowered their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $123.33.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.